Volume 3.14 | Apr 10

Hematopoiesis News 3.14, April 10, 2012
Hematopoiesis News
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY
Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML
Researchers used a conditional mouse model to show that deletion of β-catenin after CML initiation does not lead to a significant increase in survival. [Cell Stem Cell] Abstract | Press Release

Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.
PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Hematopoietic Stem Cells Lacking Ott1 Display Aspects Associated with Aging and Are Unable to Maintain Quiescence during Proliferative Stress
Scientists showed, specifically under replicative stress, one-twenty-two-1 (Ott1)-deleted hematopoietic stem cells had a significant reduction of the G0 cell cycle fraction associated with self-renewal and underwent early failure. [Blood] Abstract

Human Extramedullary Bone Marrow in Mice: A Novel In Vivo Model of Genetically Controlled Hematopoietic Microenvironment
Investigators described the development of extramedullary bone and bone marrow using human mesenchymal stromal cells and endothelial colony-forming cells implanted subcutaneously into immunodeficient mice. [Blood] Abstract

Zebrafish Screen Identifies Novel Compound with Selective Toxicity against Leukemia
To detect targeted anti-leukemia agents researchers designed a novel, high-content in vivo screen using genetically engineered, T cell-reporting zebrafish. [Blood] Abstract
| Press Release

Deletion of Tmprss6 Attenuates the Phenotype in a Mouse Model of β-Thalassemia
Researchers showed that homozygous loss of Tmprss6 in Hbbth3/+ mice improved anemia and reduced ineffective erythropoiesis, splenomegaly and iron loading. [Blood] Abstract

Using Combination Therapy to Override Stromal-Mediated Chemoresistance in Mutant FLT3-Positive AML: Synergism between FLT3 Inhibitors, Dasatinib/Multi-Targeted Inhibitors, and Janus Kinase Inhibitors
Scientists used a cell-based model mimicking stromal protection as part of an unbiased high-throughput chemical screen to identify kinase inhibitors with the potential to override microenvironment-mediated drug resistance in mutant FLT3-positive acute myeloid leukemia (AML). [Leukemia] Abstract

TET2 Is Essential for Survival and Hematopoietic Stem Cell Homeostasis
To study the function of ten-eleven-translocation 2 (TET2) in vivo, researchers analyzed Ayu17-449 mice, in which a gene trap insertion in intron 2 of TET2 reduced TET2 mRNA levels to about 20% of that found in wild-type mice. [Leukemia] Abstract

Human Olfactory Mucosa Multipotent Mesenchymal Stromal Cells Promote Survival, Proliferation and Differentiation of Human Hematopoietic Cells
Researchers investigated whether human olfactory mucosa-mesenchymal stromal cells promote the survival, proliferation and differentiation of human hematopoietic stem cells. [Stem Cells Dev] Abstract

Histone Deacetylase 3 (HDAC-3) Modulates the Expansion of Human Hematopoietic Stem Cells
Scientists identified the valproic acid target HDAC3 as a negative regulator of umbilical cord blood hematopoietic stem cell expansion. [Stem Cells Dev] Abstract

CLINICAL RESEARCH

Effect of Gemtuzumab Ozogamicin on Survival of Adult Patients with De Novo Acute Myeloid Leukemia (ALFA-0701): A Randomized, Open-Label, Phase III Study
Scientists investigated whether the addition of low fractionated-dose gemtuzumab ozogamicin to standard front-line chemotherapy would improve the outcome of patients with acute myeloid leukemia without causing excessive toxicity. [Lancet] Abstract | Press Release

Alemtuzumab in Combination with Methylprednisolone Is a Highly Effective Induction Regimen for Patients with Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial
In an attempt to improve the treatment of TP53-defective chronic lymphocytic leukemia (CLL), a multicenter phase II study was developed to evaluate alemtuzumab and methylprednisolone in combination. [J Clin Oncol]
Abstract

[Free Webinar] ALDH+ Cancer Precursor Cells in Drug Response Prediction - Register Now.

SCIENCE NEWS

New Compound Targets Key Mechanism Behind Lymphoma
Scientists have come one step closer to developing the first treatment to target a key pathway in lymphoma. [Press release from the Fox Chase Cancer Center discussing research presented at the American Association for Cancer Research (AACR) Annual Meeting 2012, Chicago] Press Release

Stand Up To Cancer Partnership Results in New, Potent Epigenetic Drug for Myelodysplastic Syndromes, Leukemia
Researchers may have discovered a new, potent epigenetic drug that could safely alter the way cancer cells function within the body. [Press release from the American Association for Cancer Research (AACR) discussing research presented at the AACR Annual Meeting 2012, Chicago]
Press Release

INDUSTRY NEWS

NIH Names Dr. Gary H. Gibbons Director of the National Heart, Lung, and Blood Institute
National Institutes of Health (NIH) Director Francis S. Collins announced the selection of Gary H. Gibbons, as the new director of the NIH’s National Heart, Lung, and Blood Institute. [National Institute of Health, United States] Press Release

Athersys Receives U.S. Patent Covering the Suppression of Graft-versus-Host Disease Associated with Hematopoietic Stem Cell Transplantation with Adult Stem Cells
Athersys, Inc. announced that it has been granted U.S. patent 8,147,824 that covers the use of non-embryonic, multipotent stem cells for the reduction in severity or prevention of Graft-versus-Host Disease. [Athersys, Inc.] Press Release

POLICY NEWS
Request for Information (RFI): Challenges and Opportunities for the Development of a Point of Care Device for the Diagnosis of Sickle Cell Disease (NOT-HL-12-140) [National Institutes of Health, United States]

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS
NEW 16th International HLA and Immunogenetics Workshop
May 28-June 3, 2012
Liverpool, United Kingdom

Visit our events page to see a complete list of events in the hematopoietic community
JOB OPPORTUNITIES

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies Inc.)

Scientist – Hematology (STEMCELL Technologies Inc.)

Scientist – hPSC (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Principal Investigators in Cancer Research (Institut de Recherches Cliniques de Montréal)

Postdoctoral Fellow in Stem Cells and Cancer (Tsinghua University)

Postdoctoral Fellow in Cytokine Signaling in Hematopoietic Stem Cells (University of Pennsylvania School of Medicine)


Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Middle East to Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us